Arena Pharma (ARNA) Posts Narrower than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
VISL, GNLN, USDP, More
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
VISL, GNLN, USDP, More
Join SI Premium – FREE
Arena Pharmaceuticals (NASDAQ: ARNA) reported Q4 loss of $0.23, $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.01 million versus the consensus estimate of $4.81 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
- Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
